 |
|
|
| |
ASSESSMENTS OF VERY-LOW-LEVEL HIV REPLICATION FOR DOLUTEGRAVIR + LAMIVUDINE (DTG + 3TC) VS DOLUTEGRAVIR + TENOFOVIR DISOPROXIL/EMTRICITABINE (DTG + TDF/FTC) IN THE GEMINI-1&-2 STUDIES THROUGH WEEK 96
|
| |
| |
17th EACS 2019 Nov 6-9 Basel
Reported by Jules Levin
Mark Underwood,1 Rimgaile Urbaityte,2 Ruolan Wang,1 Allan Tenorio,1 Brian Wynne,1
Keith Pappa,1 Justin Koteff,1 Martin Gartland,1 Jean van Wyk,3 Choy Man,1 Jörg Sievers3
1ViiV Healthcare, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Stockley Park, UK; 3ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
